Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiandan Tongluo tablets is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of acute ischemic stroke (AIS). It is typically used in patients exhibiting specific TCM syndrome patterns, such as Qi deficiency and blood stasis. The formulation aims to improve neurological function, promote microcirculation, and provide neuroprotective effects. It has been evaluated in clinical trials, including a Phase 4 multicenter study (ChiCTR2300067716) sponsored by Dongzhimen Hospital of Beijing University of Chinese Medicine, to assess its efficacy, safety, and impact on cognitive outcomes in adult stroke patients. The preparation is commercially produced by Buchang Pharmaceuticals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tiandan Tongluo tablets.